Keywords: CERA, continuous erythropoietin receptor activator; CKD, chronic kidney disease; CLCV, cutaneous leukocytoclastic vasculitis; PEG, polyethylene glycol; continuous erythropoietin receptor activator; cutaneous leukocytoclastic vasculitis; immunogenicity; polyethylene glycol; type III hypersensitivity.